Analyst Sees Increased Chance of Amylin (AMLN) Takeover Amid Bydureon Approval
Tweet Send to a FriendGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
3 Buy, 8 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade AMLN Now!
Piper Jaffray's Ian Somaiya issued a note Monday morning suggesting FDA approval of Bydureon increases chances for a takeover of Amylin (Nasdaq: AMLN).
Amylin shares are up almost 17 percent this afternoon following the news. The stock last traded at $14.20.
Somaiya believes Amylin could be worth $33 per share based on an average multiple; applying a historic multiple which assumes peak sales gets the value into the $37-$49 per share range.
Piper Jaffray maintains an Overweight rating and $17 price target on shares of Amylin.
Track all the market-moving analyst calls on shares of Amylin with our Analyst Ratings page.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Amylin shares are up almost 17 percent this afternoon following the news. The stock last traded at $14.20.
Somaiya believes Amylin could be worth $33 per share based on an average multiple; applying a historic multiple which assumes peak sales gets the value into the $37-$49 per share range.
Piper Jaffray maintains an Overweight rating and $17 price target on shares of Amylin.
Track all the market-moving analyst calls on shares of Amylin with our Analyst Ratings page.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
- UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Piper JaffrayComments
Mark as SPAM
I'm not play game in this matter. I wish, you're take this matter SERIOUSLY. It's my first time to try to invest my money and you call me Spam. My e-mail address is;
yrayner@ssafara.net
How to buy share of Amylin Pharmaceutical
Please send us the information, how to Buy Share/Stock of Amylin Pharmaceutical ASAP.
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
lot less pain for diabetic patients.
on Feb 1, 2012 01:21 PMMark as Spam | Reply to this comment
Instead of daily injections this drug allows once a week injection to diabetic patients. That is a great relief for them.